Michael A Blazing researcher
Blazing, Michael A.
VIAF ID: 317138358 (Personal)
Permalink: http://viaf.org/viaf/317138358
Preferred Forms
-
-
100 0 _ ‡a Michael A Blazing ‡c researcher
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy |
![]() |
The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure |
![]() |
Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies |
![]() |
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. |
![]() |
Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. |
![]() |
The benefit of implementing a heart failure disease management program |
![]() |
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial |
![]() |
A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response |
![]() |
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial |
![]() |
Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes |
![]() |
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial |
![]() |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome |
![]() |
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials |
![]() |
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia |
![]() |
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. |
![]() |
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial |
![]() |
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply |
![]() |
Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? |
![]() |
Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations |
![]() |
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial |
![]() |
Medication Discontinuation in the IMPROVE-IT Trial |
![]() |
Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin |
![]() |
Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status |
![]() |
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe |
![]() |
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). |
![]() |
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial |
![]() |
Premature release of data from clinical trials of ezetimibe |
![]() |
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease |
![]() |
Przedwczesne ujawnienie wyników badań z zastosowaniem ezetimibu |
![]() |
Rationale and design of IMPROVE-IT |
![]() |
Reply: Personalize and Optimize Lipid-Lowering Therapies |
![]() |
Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE |
![]() |
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis |
![]() |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial |
![]() |
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial |
![]() |
Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF |
![]() |